last Earlier of over $X.X which increase million, Thank today, X.X% announced of revenue quarter first is you we and good first morning. quarter the an year.
$X.XX diluted non-GAAP of $X.XX share. net GAAP net income diluted per also income share reported and per of We
expect similar current remaining impacted form continue of across COVID-XX to for some pandemic being to we the to medical the results were had by device the feel in the industry, These impact the negatively much of portion discussion and XXXX.
for products much current the during recognized in sell first cycle the products in completed in quarter of to sales ability our the was revenue our environment, Regarding XXXX. fourth-quarter
the to world, quarter decline first products and those acceleration our virus and Additionally, our as our continue in and infected progress efforts throughout preparing through the XXXX their for orders for focus on of decisions as impact treating COVID-XX products of deferring we customers to we into with experienced the the future. the an spread purchase
which many our access restricting customers orders. of Also our to of the future timing diminishing time, only, during sales, began healthcare may this hospital ability to workers delay generate
impacted on their We be maintain capital limit may further hospital their have operations restrictions if spending choose hospitals plans entrants and until their to stabilized.
So, despite and a higher term created uncertainties significant dynamic is believe that by we this products our will shorter for the demand return. COVID-XX, that
there were to several spots focus bright quarter, the on. for During us
and over international is revenue XX% total almost first forecast, our revenue grew first quarter from initial the exceeded The last year. channels our international
treatment efforts we infusing Second, because be some room to its an the for virus. to for proud pumps received to primary in use We're IV really overall device configuration. the able customers and isolation COVID-related control remote of as our capabilities orders contribute for this its
And third, part initial also IV of to revenue due our sets demand. from our exceeded sales forecast COVID-related in
an customers that room. During IV outside infuse positioned one utilizing we our tubing using is that isolation the that set located of were pump learned version patients quarter, to a in some room
combat wanted With do demands to healthcare the to increased on them. critical that COVID-XX current of IRadimed the has providers more shortages help placed care supplies,
days. our regular we this within tubing be to components IV use same new to in room quality are the we that It next IV expect sales and we standard finding. So, our having trouble our any extension for using build extension and tubing substituted manufacturing can few customers the tubing set is using clean tube IV simple a and expertise begin of tubing just materials are
During to in and and we our assurance succession building R&D QX, leadership ahead. part capabilities planning out as we the sales, key years of quality growth support in continue anticipate the and roles affairs, that regulatory filled will help
also at making not on changes significant roadmap continue seen product and have point. to time this our any progress We lines
I there steps testing require However, in product use phase the that new will that point out the third-parties. of are
given may many to by the testing And there shifts original schedules. stay-at-home authorities, restrictions government implemented be our
time. in supply a any are the delays products standpoint, at from Now for obtaining experiencing we this not our materials chain
Overall, our we COVID. due to business are changes to experiencing significant
supportive the During the of the this we with its on can and even make that goal pandemic longer we are of term things that health from stronger. time, company in are control the to investments focusing continuing emerging
efforts our lenses. to are looking four through we manage In through environment, this
innovation product future is one first The for growth.
mentioned, technical filled product roles progress key continue to our have recently As on leadership and make we roadmap.
its is patients. training, remote product virtual customers, infusions version facilitate ready control COVID-XX to of providing outside to our one or second for support serving delivery The through for from pumps modifying capabilities we our IV our isolation care a tubing whether IV room or our of customers' stand supplying critical an
is our taking employees. care The third lens of
working a and that where at well-being have feasible. headquarters their cleaning time. this trained highly arrangements support and have during health our These enhanced range procedures workforce We implemented policies facility to from several remote
our with steps reduced and restrictions complying containment. contain The hours several costs, entry teams. sales We've clinical to implementing already and taken in travel cost by support field some and fourth departments including is
will continue additional we'll situation steps four as through look develops, evaluate the We to taking lenses and needed. if these
to it the I'll Chris results. Now, to financial over summarize turn
